Symbiotec Pharmalab Limited has scheduled a meeting of its Board of Directors for Thursday, November 5, 2026. The primary agenda items for the meeting include:
- Consideration and approval of the Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2026
- Consideration and approval of the Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2026
- Review of the Limited Review Report accompanying the financial results
- Consideration of any other matters with the permission of the Chair
The company also confirmed that the trading window for dealing in securities by all designated persons and their immediate relatives remains closed, as previously intimated on September 29, 2026. The trading window closure will continue until 48 hours after the declaration of the Unaudited Financial Results for the quarter and half year ended September 30, 2026.
This information is available on the company's website at www.symbiotec.com. The disclosure is signed by Salil Jain, Company Secretary and Compliance Officer (Membership No. A41610).